Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 104242 | 4.345 |
09:34 ET | 65893 | 4.305 |
09:36 ET | 8891 | 4.32 |
09:38 ET | 5920 | 4.3201 |
09:39 ET | 117467 | 4.295 |
09:41 ET | 5441 | 4.315 |
09:43 ET | 19253 | 4.305 |
09:45 ET | 8657 | 4.31 |
09:48 ET | 4586 | 4.3 |
09:50 ET | 2790 | 4.3001 |
09:52 ET | 14723 | 4.305 |
09:54 ET | 25360 | 4.305 |
09:56 ET | 14605 | 4.31 |
09:57 ET | 3635 | 4.3 |
09:59 ET | 8639 | 4.255 |
10:01 ET | 13704 | 4.27 |
10:03 ET | 7094 | 4.265 |
10:06 ET | 5936 | 4.27 |
10:08 ET | 4045 | 4.27 |
10:10 ET | 6904 | 4.285 |
10:12 ET | 34668 | 4.265 |
10:14 ET | 11393 | 4.255 |
10:15 ET | 40243 | 4.25 |
10:17 ET | 19305 | 4.245 |
10:19 ET | 3461 | 4.245 |
10:21 ET | 3428 | 4.245 |
10:24 ET | 44139 | 4.27 |
10:26 ET | 2040 | 4.27 |
10:28 ET | 3800 | 4.27 |
10:30 ET | 7142 | 4.285 |
10:32 ET | 22536 | 4.27 |
10:33 ET | 6005 | 4.27 |
10:35 ET | 1390 | 4.27 |
10:37 ET | 28906 | 4.2801 |
10:39 ET | 11335 | 4.29 |
10:42 ET | 19625 | 4.29 |
10:44 ET | 14262 | 4.28 |
10:46 ET | 13269 | 4.25 |
10:48 ET | 1962 | 4.25 |
10:50 ET | 2249 | 4.25 |
10:51 ET | 2926 | 4.2575 |
10:53 ET | 3495 | 4.255 |
10:55 ET | 26989 | 4.26 |
10:57 ET | 8187 | 4.255 |
11:00 ET | 4115 | 4.255 |
11:02 ET | 4584 | 4.255 |
11:04 ET | 2854 | 4.25 |
11:06 ET | 11265 | 4.245 |
11:08 ET | 18422 | 4.25 |
11:09 ET | 17762 | 4.24 |
11:11 ET | 46925 | 4.24 |
11:13 ET | 10980 | 4.235 |
11:15 ET | 2939 | 4.23 |
11:18 ET | 5369 | 4.23 |
11:20 ET | 9032 | 4.22 |
11:22 ET | 11892 | 4.21 |
11:24 ET | 4161 | 4.2199 |
11:26 ET | 40122 | 4.225 |
11:27 ET | 25384 | 4.22 |
11:29 ET | 5473 | 4.23 |
11:31 ET | 5788 | 4.225 |
11:33 ET | 16542 | 4.225 |
11:36 ET | 18986 | 4.21 |
11:38 ET | 21754 | 4.2 |
11:40 ET | 9954 | 4.204 |
11:42 ET | 44502 | 4.2093 |
11:44 ET | 7984 | 4.205 |
11:45 ET | 33141 | 4.2 |
11:47 ET | 5524 | 4.2 |
11:49 ET | 47209 | 4.19 |
11:51 ET | 8385 | 4.2 |
11:54 ET | 110162 | 4.21 |
11:56 ET | 190660 | 4.22 |
11:58 ET | 9553 | 4.205 |
12:00 ET | 3240 | 4.205 |
12:02 ET | 26315 | 4.205 |
12:03 ET | 16714 | 4.19 |
12:05 ET | 31122 | 4.205 |
12:07 ET | 79015 | 4.21 |
12:09 ET | 14360 | 4.215 |
12:12 ET | 10808 | 4.21 |
12:14 ET | 22727 | 4.2 |
12:16 ET | 7757 | 4.205 |
12:18 ET | 5569 | 4.2 |
12:20 ET | 12463 | 4.205 |
12:21 ET | 3898 | 4.205 |
12:23 ET | 20979 | 4.195 |
12:25 ET | 9854 | 4.2 |
12:27 ET | 2509 | 4.1999 |
12:30 ET | 41613 | 4.19 |
12:32 ET | 25640 | 4.185 |
12:34 ET | 18761 | 4.19 |
12:36 ET | 11282 | 4.185 |
12:38 ET | 5939 | 4.1825 |
12:39 ET | 3848 | 4.185 |
12:41 ET | 98568 | 4.17 |
12:43 ET | 8113 | 4.17 |
12:45 ET | 37369 | 4.1679 |
12:48 ET | 77264 | 4.19 |
12:50 ET | 88039 | 4.195 |
12:52 ET | 11160 | 4.185 |
12:54 ET | 1659 | 4.19 |
12:56 ET | 2390 | 4.185 |
12:57 ET | 2147 | 4.1898 |
12:59 ET | 7076 | 4.19 |
01:01 ET | 2620 | 4.19 |
01:03 ET | 2372 | 4.185 |
01:06 ET | 2267 | 4.185 |
01:08 ET | 2200 | 4.185 |
01:10 ET | 2916 | 4.19 |
01:12 ET | 24742 | 4.195 |
01:14 ET | 41051 | 4.2009 |
01:15 ET | 12635 | 4.195 |
01:17 ET | 4185 | 4.195 |
01:19 ET | 2210 | 4.195 |
01:21 ET | 29817 | 4.185 |
01:24 ET | 17202 | 4.185 |
01:26 ET | 4374 | 4.185 |
01:28 ET | 5495 | 4.185 |
01:30 ET | 18144 | 4.17 |
01:32 ET | 34581 | 4.16 |
01:33 ET | 7279 | 4.16 |
01:35 ET | 31829 | 4.1622 |
01:37 ET | 4160 | 4.16 |
01:39 ET | 34697 | 4.185 |
01:42 ET | 25467 | 4.175 |
01:44 ET | 1400 | 4.175 |
01:46 ET | 44999 | 4.19 |
01:48 ET | 3200 | 4.185 |
01:50 ET | 12988 | 4.18 |
01:51 ET | 4922 | 4.185 |
01:53 ET | 7212 | 4.185 |
01:55 ET | 8305 | 4.185 |
01:57 ET | 5120 | 4.18 |
02:00 ET | 21551 | 4.175 |
02:02 ET | 35820 | 4.175 |
02:04 ET | 15237 | 4.183 |
02:06 ET | 1691 | 4.185 |
02:08 ET | 18821 | 4.2 |
02:09 ET | 910 | 4.2 |
02:11 ET | 1859 | 4.195 |
02:13 ET | 2850 | 4.2 |
02:15 ET | 19699 | 4.195 |
02:18 ET | 5367 | 4.19 |
02:20 ET | 5896 | 4.19 |
02:22 ET | 3033 | 4.19 |
02:24 ET | 5157 | 4.19 |
02:26 ET | 3772 | 4.19 |
02:27 ET | 22763 | 4.19 |
02:29 ET | 7516 | 4.19 |
02:31 ET | 7992 | 4.19 |
02:33 ET | 4652 | 4.195 |
02:36 ET | 8902 | 4.195 |
02:38 ET | 7217 | 4.195 |
02:40 ET | 5529 | 4.195 |
02:42 ET | 8813 | 4.19 |
02:44 ET | 11530 | 4.195 |
02:45 ET | 9761 | 4.195 |
02:47 ET | 47731 | 4.185 |
02:49 ET | 53058 | 4.175 |
02:51 ET | 18695 | 4.185 |
02:54 ET | 10519 | 4.185 |
02:56 ET | 15529 | 4.185 |
02:58 ET | 51410 | 4.185 |
03:00 ET | 20313 | 4.19 |
03:02 ET | 21087 | 4.185 |
03:03 ET | 11457 | 4.185 |
03:05 ET | 41518 | 4.18 |
03:07 ET | 10088 | 4.175 |
03:09 ET | 6352 | 4.18 |
03:12 ET | 6387 | 4.17 |
03:14 ET | 32578 | 4.1697 |
03:16 ET | 30703 | 4.175 |
03:18 ET | 14286 | 4.175 |
03:20 ET | 22887 | 4.19 |
03:21 ET | 4709 | 4.19 |
03:23 ET | 36249 | 4.185 |
03:25 ET | 11270 | 4.18 |
03:27 ET | 5237 | 4.18 |
03:30 ET | 8394 | 4.185 |
03:32 ET | 17078 | 4.185 |
03:34 ET | 10209 | 4.185 |
03:36 ET | 14795 | 4.18 |
03:38 ET | 133463 | 4.185 |
03:39 ET | 74681 | 4.185 |
03:41 ET | 16648 | 4.185 |
03:43 ET | 16390 | 4.185 |
03:45 ET | 37601 | 4.19 |
03:48 ET | 42813 | 4.2 |
03:50 ET | 16528 | 4.195 |
03:52 ET | 89505 | 4.17 |
03:54 ET | 27036 | 4.18 |
03:56 ET | 110421 | 4.18 |
03:57 ET | 137646 | 4.185 |
03:59 ET | 737129 | 4.17 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.6B | -12.0x | --- |
Celldex Therapeutics Inc | 2.6B | -13.0x | --- |
MoonLake Immunotherapeutics | 2.7B | -53.5x | --- |
Xenon Pharmaceuticals Inc | 2.8B | -13.5x | --- |
Agios Pharmaceuticals Inc | 2.5B | -6.7x | --- |
Structure Therapeutics Inc | 2.3B | -16.7x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.6B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.48 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -12.0x |
Price/Sales (TTM) | 4,950.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.